Opinion|Videos|February 17, 2025
Expectations for Efficacy and Duration of Response With Systemic Atopic Dermatitis Treatments
Panelists discuss treatment expectations for newer systemic agents, highlighting data on efficacy onset and persistence, including rapid improvement in pruritus with dupilumab by week 2 (SOLO trials), early Investigator Global Assessment (IGA) and Eczema Area and Severity Index (EASI)-75 improvement with lebrikizumab by week 2 to 4 (ADvocate trials), and EASI-75 improvement with tralokinumab by week 4 (ECZTRA 6 trial), emphasizing the importance of setting realistic expectations with patients and caregivers regarding the onset of action and duration of treatment.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Let’s shift now to treatment expectations. What are the data about efficacy onset and persistence when considering these newer systemic agents?
- How do you set expectations with patients starting on systemic treatment and their caregivers in terms of onset of action and duration of treatment?
- Dupilumab in the SOLO trials showed improvement on Peak Pruritus Numerical Rating Scale score at week 2 (in adults).
- Lebrikizumab in the ADvocate trials showed some IGA improvement at week 4 and some EASI-75 improvement at week 2.
- Tralokinumab in the ECZTRA 6 trial showed some EASI-75 improvement at 4 weeks (in adolescents).
Advertisement
Related to this article
For Eczema Awareness Month, Keira Barr, MD, explains the stress-itch cycle in atopic dermatitis and questions to uncover its hidden burden in clinic.
Stephan Weidinger, MD, PhD, discusses 5-year ADlong data showing durable skin clearance and itch control with lebrikizumab in atopic dermatitis.
Interim RAINIER data show povetacicept reduced proteinuria by 52.0% and resolved hematuria in 85% of patients at week 36, ahead of a November PDUFA date.
Interim I CAN data show ravulizumab reduced proteinuria by 43.4% vs placebo at week 34, supporting its FDA accelerated approval in IgA nephropathy.
Lorundrostat cut systolic BP by 9.6 mm Hg and UACR by 52.2% vs placebo in participants with CKD and uncontrolled hypertension in Launch-HTN.
The ENRICH-AF trial ultimately did not demonstrate edoxaban’s efficacy, highlighting the need for further stroke prevention strategies for this patient population.
Final TELIGAN data show telitacicept cut confirmed 30% eGFR decline by 89% and reduced proteinuria by 60.7% vs placebo over 2 years in IgA nephropathy.
Participants described how payer requirements and documentation of steroid exposure shape biologic access.
Advertisement
Advertisement
Trending on HCPLive
1
Retatrutide Lowers Albuminuria, Glomerular Pressure in Obesity and CKD
2
AD109 Yields Numerically Greater OSA Improvements in Postmenopausal Women
3
Sleeve Gastrectomy Improves Heart, Kidney MRI Markers in Youth-Onset T2D
4
TELIGAN: Telitacicept Preserves eGFR Through 2 Years in IgA Nephropathy
5